ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1249

Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

Shilpa Venkatachalam1, Kelly Gavigan2, Erik Stone3, Angela Degrassi2, Laura Stradford4, David Curtis2, Esteban Rivera5 and Jeffrey Curtis6, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Long Island City, NY, 6University of Alabama at Birmingham, Hoover, AL

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), COVID-19, Patient reported outcomes, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living with these conditions, and guide goal setting and treatment that is more personalized. We retrospectively analyzed PRO reporting over a 4-year period, which included the COVID-19 pandemic, to understand if PRO selection differed across the 4 years and if there were selection differences between rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) diagnoses.

Methods: Upon joining the PatientSpot research registry, patients with axSpA (including ankylosing spondylitis and non-radiographic axSpA), PsA, and RA were invited to select PRO symptom measures that they felt were important to digitally track for their condition via health assessments in the registry. Tracked assessments could be changed at the discretion of the patient. Assessments included but were not limited to domains assessing pain and its impact on activity, physical function, sleep disturbance, fatigue, social isolation, and mental health.

Results: A total of 6,308 patients with the specified conditions provided 277,574 PROs across four years from June 1, 2020, to May 31, 2024. Of those, 65.3% reported having RA, 20.1% PsA, and 14.7% axSpA. Out of the total assessments captured, Year 3 (6/1/2022 – 5/31/2023) had the most completed assessments (39.1%) compared to the other years, despite seeing a decline in total patients contributing assessments (Figure 1). The most used assessments across the 3 conditions were PROMIS Pain Interference (11.5%), Physical Function (9.5%), and Sleep Disturbance (9.4%) (Table 2). Notably, the OMERACT RA flare instrument was also used among PsA patients, with 4.5% of PsA patients reporting on flares captured via the RA Flare assessment.

Conclusion: The increase in assessments in Year 3 may indicate changes in healthcare practices or disease management strategies that resulted from the COVID-19 pandemic, such as increased utility of telehealth and remote monitoring. These practices may have led to changes in how patients manage their health condition, underscoring the need to better understand PROs and their utility. PROMIS Pain Interference, Physical Function, and Sleep Disturbance were the most selected measures across the three conditions, indicating the need for more targeted pain management strategies that address patients’ mobility and sleep. The use of the OMERACT RA flare instrument by PsA patients underscores its broader perceived applicability in capturing disease activity and flare-ups in other types of inflammatory arthritis, and the need for disease-specific flare assessment tools. Understanding the impact of inflammatory arthritis from the patient’s perspective through patient-reported outcomes data provides valuable insights into the daily challenges and quality of life issues that patients face and can provide valuable insights for optimizing patient care and guiding future research on arthritis management.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Venkatachalam: None; K. Gavigan: Global Healthy Living Foundation, 3; E. Stone: None; A. Degrassi: None; L. Stradford: AbbVie, 5, Amgen, 5, BMS, 5, Eli Lilly, 5, Global Healthy Living Foundation, 3, Pfizer, 5; D. Curtis: None; E. Rivera: Global Healthy Living Foundation, 3; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Aqtual, 5, Bendcare, 2, 5, Bristol-Myers Squibb(BMS), 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, FASTER, 2, 4, Genentech, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Moderna, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sanofi, 2, 5, UCB Pharma, 2, 5.

To cite this abstract in AMA style:

Venkatachalam S, Gavigan K, Stone E, Degrassi A, Stradford L, Curtis D, Rivera E, Curtis J. Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/patient-reported-outcomes-in-inflammatory-arthritis-a-four-year-retrospective-analysis-via-the-patientspot-research-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-in-inflammatory-arthritis-a-four-year-retrospective-analysis-via-the-patientspot-research-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology